Frontlight ResearchEarly access
CompletedNo phase
Real-World Study on the Burden of Hidradenitis Suppurativa
Key facts
- Who runs it
- PeriPharm
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 20 Feb 2026
- Ended
- 1 Oct 2026
- Type of study
- Observational
- Treatments tested
- No Intervention: Observational Cohort
- Record updated
- 8 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patient diagnosed with HS
- Aged ≥18 years
- Able to read and understand French or English
- Willing and able to provide written informed consent
Who cannot take part
- Participation in an interventional study for HS
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.
The group in the trial
- Patient with HS
Patient diagnosed with HS
Treatment: No Intervention: Observational Cohort
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 8 October 2026